Anbio Biotechnology Class A Ordinary Shares (NNNN) DCF: History & Chart

Anbio Biotechnology Class A Ordinary Shares(NNNN)

Medical - Instruments & Supplies · Frankfurt am Main, HE

$4.91+0.08 (+1.66%)

Delayed quote: Oct 6, 2026, 2:13 PM EDT

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Frankfurt am Main, HE

27 employees

www.anbio.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Michael Lau

View full financials

Anbio Biotechnology Class A Ordinary Shares (NNNN) DCF Valuation

Why we don't show a single “fair value” for NNNN

A trailing-FCF DCF can't fairly anchor Anbio Biotechnology Class A Ordinary Shares right now — free cash flow is currently depressed by a heavy investment cycle while revenue keeps growing. For a company in this position, trailing free cash flow understates what the business actually earns for owners, so any “fair value” built on it would be misleadingly low. Off today's cash-flow base, no plausible growth rate bridges to the current price — the market is valuing normalized future cash flows, not the depressed base. The model scenarios below are shown for reference only.

Scenario	FCF growth (fading to 2.5%)	Discount	Value / share
Conservative	10.5%/yr	12.5%	$0.65
Base case	13.5%/yr	11.5%	$0.77
Optimistic	16.5%/yr	10.5%	$0.93
Third-party model estimate (FMP)	independent reference · retrieved Oct 6, 2026 · assumptions not provided		$0.70

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Price|PE Ratio|FCF Yield|All Metrics

Current Price

$4.91

Market-Implied Growth

N/A

Base-Case Model Value

$0.77

model output — not a price target

NNNN DCF Fair Value Calculator

Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for NNNN (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.

FCF Growth Rate13.5%/yr

Historical FCF CAGR: N/A

Discount Rate (WACC)11.5%

Terminal Growth2.5%

Projection Years10yr

Base inputs: FCF $1.5M · 0.04B shares · net cash $7.8M

Estimated Fair Value

$0.77

-84.3% vs $4.91

Current price$4.91

Third-party model estimate (FMP)$0.70

Sensitivity — fair value by discount rate × terminal growth

How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 13.5%/yr FCF growth and 10-year horizon fixed. Green = above today's $4.91; red = below. Your current case is outlined.

WACC ↓ / Terminal →	1.50%	2.00%	2.50%	3.00%	3.50%
9.5%	$0.87	$0.91	$0.95	$1.00	$1.06
10.5%	$0.79	$0.82	$0.85	$0.89	$0.93
11.5%	$0.72	$0.75	$0.77	$0.80	$0.83
12.5%	$0.67	$0.69	$0.71	$0.73	$0.75
13.5%	$0.62	$0.64	$0.65	$0.67	$0.69